Afrezza Safety and Pharmacokinetics Study in Pediatric Patients
Status:
Suspended
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
Primary Objective:
-To assess the safety and tolerability of Afrezza in children ages 4 to 17 years with type 1
diabetes mellitus (T1DM).
Secondary Objectives:
- To assess the ability to titrate the prandial and supplemental doses of Afrezza at each
meal.
- To assess pharmacokinetics (PK) following a prandial dose of Afrezza in children ages 4
to 17 years with T1DM.